Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00057811 · OUTCOME

Minimal Residual Disease

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma · Source last updated 2014-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of samples analyzed
Interval / dispersion
95% Confidence Interval
Time frame
Not Provided

What was measured

The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section).

Analysis population: Population analyzed included patients submitting samples for minimal disease assay at end induction

Groups in this outcome

Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)

Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.

Group C (Chemotherapy, Monoclonal Antibody Therapy)

Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)32
Group C (Chemotherapy, Monoclonal Antibody Therapy)10

Reported measurements

Source class 1
Values in percentage of samples analyzed · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)22Not reported1140Not reported
Group C (Chemotherapy, Monoclonal Antibody Therapy)70Not reported3593Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11
        upper Limit
        40
        value
        22
      2. group Id
        OG001
        lower Limit
        35
        upper Limit
        93
        value
        70
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    2. group Id
      OG001
      value
      10
    units
    Participants
description
The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section).
dispersion Type
95% Confidence Interval
groups
  1. description
    Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
    id
    OG000
    title
    Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)
  2. description
    Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
    id
    OG001
    title
    Group C (Chemotherapy, Monoclonal Antibody Therapy)
param Type
NUMBER
population Description
Population analyzed included patients submitting samples for minimal disease assay at end induction
reporting Status
POSTED
time Frame
Not Provided
title
Minimal Residual Disease
type
PRIMARY
unit Of Measure
percentage of samples analyzed

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice